Inhibition of NF-kB activity blocked the HER2-mediated production of CCL2, which, in an in vivo model, was further found to impair recruitment of immune cells and reduce tumour sensitivity to trastuzumab [86]. The gene discussed is NFKB1; the disease is neoplasm.